Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Karen E. Hoffman, Paul L. Nguyen, Dana E. Rathkopf, Amado J. Zurita, Daniel Eidelberg Spratt, Robert Timothy Dess, Stanley L. Liauw, Russell Zelig Szmulewitz, David Johnson Einstein, Glenn Bubley, James B. Yu, Yi An, Anthony C. Wong, Felix Y Feng, Rana R. McKay, Brent S. Rose, Kee-Young Shin, Adam S. Kibel, Mary-Ellen Taplin, Marisa Kollmeier
Institutions: The University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, Memorial Sloan Kettering Cancer Center, Case Western Reserve University, Michigan Medicine, University of Chicago, University of Chicago Medical Center, Beth Israel Deaconess Medical Center, Smilow Cancer Hospital, Yale New Haven Hospital, University of California, San Francisco, University of California San Diego, Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4391303143